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Abstract
The development of safe, effective and affordable drug combinations against malaria in Africa is a
public health priority. Methylene blue (MB) has a similar mode of action as chloroquine (CQ) and
has moreover been shown to selectively inhibit the Plasmodium falciparum glutathione reductase. In
2004, an uncontrolled dose-finding study on the combination MB-CQ was performed in 435 young
children with uncomplicated falciparum malaria in Burkina Faso (CQ monotherapy had a > 50%
clinical failure rate in this area in 2003). Three serious adverse events (SAE) occurred of which one
was probably attributable to the study medication. In the per protocol safety analysis, there were
no dose specific effects. The overall clinical and parasitological failure rates by day 14 were 10%
[95% CI (7.5%, 14.0%)] and 24% [95% CI (19.4%, 28.3%)], respectively. MB appears to have efficacy
against malaria, but the combination of CQ-MB is clearly not effective in the treatment of malaria
in Africa.
Background
The increasing resistance of Plasmodium falciparum to
existing safe and affordable drugs such as chloroquine
(CQ) and pyrimethamine-sulfadoxine severely threatens
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the available options for malaria control in sub-Saharan
Africa (SSA) [1]. To maximise efficacy and to minimise
resistance development, malaria combination therapy has
become a new paradigm [2]. Although a small number of
new malaria drugs including artemisinin derivates have
been developed in recent years, these are usually too
expensive for unsubsidised use in SSA.
Methylene blue (MB) has already been used some 100
years ago against malaria but it disappeared when CQ and
other drugs entered the market [3]. MB, a specific inhibi-
tor of P. falciparum glutathione reductase, has the poten-
tial to reverse CQ resistance and it prevents the
polymerization of haem into haemozoin similar to 4-
amino-quinoline antimalarials [4]. It has recently been
shown that the combination MB-CQ is safe in adults and
children with and without G6PD deficiency [5-7]. How-
ever, oral MB given twice daily (4 mg/kg/day) together
with a standard dose of CQ over three days was not effec-
tive in the treatment of uncomplicated malaria in young
children of Nouna town in Burkina Faso in 2003. The day
14 CF rate was 53.7%, 95% CI 37.4–69.3, in the CQ con-
trol arm [7]. The aim of the present study was to assess the
safety and efficacy of higher and more frequent MB doses
in combination with CQ in a comparable study popula-
tion in the same area.
Materials and methods
A single centre uncontrolled trial with three dose levels
was conducted during the rainy season 2004 at the district
hospital of Nouna in north-western Burkina Faso, an area
of intense malaria transmission [8]. Febrile children from
Nouna town were invited to the hospital for examination
and treatment. Inclusion criteria were age 6–59 months,
uncomplicated malaria (axillary temperature ≥ 37.5°C
and ≥ 2.000 P. falciparum asexual parasites per μl blood),
haemoglobin  ≥ 8 g/dl, absence of severe malaria and
other significant disease, and informed written consent.
The study was conducted in accordance with the interna-
tionally established principles for GCP and controlled by
a data safety monitoring board (DSMB). The protocol was
approved by the Ethics Committee of the University of
Heidelberg and the local Ethics Committee in Burkina
Faso.
Children were recruited for the three dose levels sequen-
tially. In addition to receiving a total CQ dose of 25 mg/
kg (10 mg/kg on days 0 and 1, and 5 mg/kg on day 2),
study children received total doses of MB of 36, 54, and 72
mg/kg respectively. At each dose level children were
block-randomized by envelope to two or four MB doses
per day. MB (Mayrhofer Pharmazeutika, Linz/Austria)
was given as a 2.3% solution with fruit flavouring and
honey supplement to mask the bitter taste. CQ (tablets or
syrup) was taken from the essential drug stock of the hos-
pital. In case of vomiting within 30 minutes after intake,
the drugs were re-administered once.
The dose escalation process for a dosage regimen went
into the next higher dosage level if the safety (i.e. one-
sided 95% CI for the incidence of relevant adverse events
below 0.1) and the efficacy criterion (i.e. one-sided 95%
CI for the incidence of CF below 0.15) were fulfilled at
most in one dosage level.
Study participants were hospitalized for 72 hours. Treat-
ment failures were managed according to national guide-
lines. Children were systematically examined on day 0, 1,
2, 3, 4 and 14. Blood samples were processed with stand-
ard methods in the laboratory of the Centre de Recherche en
Santé de Nouna (CRSN) [6]. Methaemoglobin formation
was monitored twice daily on day 0 and once on day 1, 2
and 3. Other laboratory parameters like liver enzymes,
serum creatinine or the phenotypical G6PD status were
available at any time if clinically indicated. Based on filter
paper blood samples, the G6PD genotype was determined
in Germany [9].
Treatment outcomes were classified according to the
WHO guidelines from 2003 as adequate clinical and par-
asitological response (ACPR), early treatment failure
(ETF), late clinical failure (LCF), late parasitological fail-
ure (LPF) and clinical failure (CF = ETF+LCF) [10].
Assuming a 10% drop-out rate, 72 patients per group and
dose level were needed to discover relevant safety and effi-
cacy scenarios with a power of 80% and to avoid a false
positive dose effect with probability of 95%. The sample
size estimation assumed the independence of the efficacy
outcome and the safety outcome. The null hypothesis had
to be rejected in each level if the incidence of the relevant
study adverse events fell below 10%. For treatment out-
comes, the null hypothesis was rejected if the CF rate was
below 15%. The safety analysis was based on the children
who have received at least one dose of CQ-MB (FAS = full
analysis set). Efficacy data were assessed in the population
of children who received the full course of treatment (per
protocol population, PP). All data were double entered
and SAS® 8.2 was used to analyse the data. Continuous
variables in two groups were compared with the nonpara-
metric Wilcoxon-Mann-Whitney (WMW) or Kruskal-Wal-
lis Test (KW), categorical variables with Chi-square-test
(Chi). The clinical failure rates were analysed using the
two fixed factors (group and level) in a logistic regression
model, likelihood ratio tests (LR) were conducted.
Results
Overall, 435 children were included into the study, 412 in
the FAS analysis and 364 in the PP analysis (Figure 1). The
lower number in level 3 is explained by an insufficientMalaria Journal 2006, 5:84 http://www.malariajournal.com/content/5/1/84
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number of malaria cases occurring at the end of the rainy
season. There were no significant differences in baseline
parameters between the two randomized groups. Between
the three dose levels there were differences in prior treat-
ment (37.4%, 30.0%, 21.7%, pChi = 0.0233), age (31.6,
32.1, 36.9 months, pKW = 0.0124), and in methaemo-
globin (1.5, 1.1, 1.1%, pKW < 0.0001). Overall 88/409
(21.5%) of FAS children were found to be genotypically
G6PD deficient (50 heterozygote, 38 homo- or hemizy-
gote).
There were three serious adverse events in 412 patients
(0.7%, 95% CI 0.2–2.1). During dose level 2, one child
progressed to severe malaria within 24 hours of inclusion
into the study and one child died of diarrhoea on day 8.
During dose level 3, in one G6PD deficient male child the
Hb dropped from 8.7 g/dl at inclusion to 4.7 g/dl on day5
but improved afterwards on iron supplementation. Clini-
cally there were no signs of haemolysis and total serum
bilirubin was normal on day 3. In seven other children the
Hb value dropped by more than 3 g/dl, three of these were
found to be G6PD deficient. There were no major differ-
ences in the incidence of other adverse events between
study groups and dose levels (data not shown).
Efficacy outcomes are given in Table 1. The overall day 14
CF and LPF rates were 38/364 (10.4%, 95% CI 7.5–14.0)
and 86/364 (23.6%, 95% CI 19.4–28.3) respectively with-
out interactions between groups and drug levels (see
Table 1).
Discussion
The results of this study provide some indirect evidence
that MB, a cheap drug which is registered in most coun-
tries, could be effective as treatment of uncomplicated
malaria in SSA. Compared to the low efficacy demon-
strated in a previous study where a low dosage of MB (12
mg per kg over three days) in combination with CQ was
used, the CQ-MB combination in this study appeared to
be more effective at three to six times higher MB doses
(36–72 mg per kg over three days) [7]. However, although
the present study was done during a comparable time
period and in a comparable study population, the results
of these two studies are not fully comparable due to pos-
sibly different incidences of other febrile diseases as well
as differences in malaria transmission intensity between
the year 2003 and 2004.
There were no differences in efficacy between a two times
and a four times daily regimen in this dose-finding study;
this suggests that a more than twice daily MB regimen
Trial profile Figure 1
Trial profile.
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would have no benefits. MB has a rather short half-life
which has been estimated at 5–6 hours [4]. However, our
own data point to a slightly longer half-life of 15 hours
(Walter-Sack, unpublished). As artemisinin drugs have an
even shorter half-life and have been shown to be effective
with once daily regimens, a once daily regimen of MB may
also be sufficient [1,11,2]. This could be clarified in future
studies.
Methylene blue belongs to a group of drugs considered to
potentially cause haemolysis when given to persons with
G6PD deficiency [12]. However, in most of SSA, the class
III G6PD deficiency dominates, where there remains an
enzyme activity of 15–25%, compared to only 0–5% in
class II deficiency [12]. It is reassuring that there was no
evidence for haemolysis being a major side effect in an
overall group of 593 children treated with MB during the
2003 and 2004 studies in Burkina Faso, which included a
total of 112 children with G6PD deficiency [7]. However,
in one child of this dose finding study an episode of
haemolysis may have occurred and could have been
attributed to MB. Only larger studies would be able to
fully quantify this hypothetical risk of treating malaria in
African children with MB. This also concerns other drugs
which may lead to haemolysis in G6PD deficiency, such
as dapsone, a drug recently approved for malaria therapy
in combination with chloroproguanil [13].
Given the potential of CQ resistance reversal, the combi-
nation of CQ with MB was studied in trials conducted in
Burkina Faso [4,6,7]. However, this study has clearly
shown that the CQ-MB combination was not sufficiently
effective even at higher MB doses. As follow-up was only
for 14 days, it can be expected that a 28 day follow-up
would have shown even higher clinical and parasitologi-
cal failure rates. A factor that has probably contributed to
this result is the (previously unknown) high CQ back-
ground resistance in the urban Nouna study area [7]. In
analogy to the artemisinin combination schemes, MB
may need to be combined with a locally effective partner
drug when given in a three day regimen [1,2,11]. Moreo-
ver, it has recently been shown that CQ is antagonistic to
MB when combined against P. falciparum in vitro, which
may further explain the impairment of efficacy observed
[14].
In conclusion, this study has provided indirect evidence
for efficacy of MB in the treatment of uncomplicated falci-
parum malaria in SSA but has clearly shown that the com-
bination CQ-MB is not useful in the treatment of malaria
in SSA.
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